<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00728806</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU-PROPDBM</org_study_id>
    <nct_id>NCT00728806</nct_id>
  </id_info>
  <brief_title>Biomarker for Peritoneal Ultrafiltration Failure</brief_title>
  <official_title>Biomarker for Early Detection and Intervention of Peritoneal Ultrafiltration Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the peritoneal tissue, serum and dialysate proteins of peritoneal&#xD;
      dialysis (PD) patients with different types of peritoneal solute transport by differential&#xD;
      proteomics techniques.&#xD;
&#xD;
      This study will be performed to identify the molecular difference between different types of&#xD;
      peritoneal solute transport and explore biomarker for early detection as well as early&#xD;
      intervention of peritoneal ultrafiltration failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ultrafiltration failure (UFF) is an important cause of technical failure in PD patients. It&#xD;
      may develop over time and is, therefore, especially important in longterm PD. However, the&#xD;
      study on UFF is very limited so far, there are still lack of biomarker for early detection&#xD;
      and intervention of UFF.&#xD;
&#xD;
      Proteomics uses a rapidly evolving group of technologies to identify, quantify, and&#xD;
      characterize a global set of proteins. It is characterized by high-throughput, high&#xD;
      specificity and high-sensitivity. Therefore, proteomics has become a major focus of recent&#xD;
      medical research.&#xD;
&#xD;
      This study will examine the peritoneal tissue, serum and dialysate proteins of continuous&#xD;
      ambulatory peritoneal dialysis (CAPD) patients with different types of peritoneal solute&#xD;
      transport by differential proteomics techniques. Correlation analysis will be used for the&#xD;
      relationship between clinical data and the differential proteins, as well as verification of&#xD;
      the differential proteins in the peritoneal tissue, serum and dialysate of patients with UFF.&#xD;
      This study will be performed to identify the molecular difference between different types of&#xD;
      peritoneal solute transport and explore biomarker for early detection as well as early&#xD;
      intervention of peritoneal ultrafiltration failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
  </study_design_info>
  <enrollment type="Actual">40</enrollment>
  <condition>Continuous Ambulatory Peritoneal Dialysis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peritoneal tissue will be collected at the time of peritoneal dialysis catheter insertion or&#xD;
      extubation. Serum and dialysate samples will be collected for protein analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatients and outpatients in the peritoneal dialysis center of 1st Affiliated Hospital,&#xD;
        Sun Yat-Sen University&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Continuous ambulatory peritoneal dialysis patients whose primary disease is chronic&#xD;
             glomerulonephritis, The range of age is 20 to 65 year old.&#xD;
&#xD;
          -  serum albumin level ≥ 35 g/L.&#xD;
&#xD;
          -  Residual GFR ≥ 2 ml/min/1.73 m2.&#xD;
&#xD;
          -  500 ml/d ≤ urine output ≤ 1000 ml/d.&#xD;
&#xD;
          -  Subjects who agree to participate in the study and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are secondary nephropathy.&#xD;
&#xD;
          -  Patients with congestive heart failure, angina, myocardial infarction, severe valvular&#xD;
             heart disease, malignant hypertension, hypertensive encephalopathy or cerebrovascular&#xD;
             accident.&#xD;
&#xD;
          -  Patients with chronic liver disease, dyscrasia, psychiatric disorder, alcohol or drug&#xD;
             abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xueqing Yu, M.D. &amp; Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>1st Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital, Sun Yet-sen University</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>August 1, 2008</study_first_submitted>
  <study_first_submitted_qc>August 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2008</study_first_posted>
  <last_update_submitted>May 21, 2015</last_update_submitted>
  <last_update_submitted_qc>May 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xue Qing Yu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Continuous Ambulatory Peritoneal Dialysis</keyword>
  <keyword>Ultrafiltration failure</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Proteomics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

